. 2022 Apr 27;36(3):231–323. doi: 10.1007/s40259-022-00529-7

Table 9.

Alternative modes of delivery for antibodies targeting SARS-CoV-2

Candidate	Sponsor	SOD	Format	Dose (mg)	ROA	MOA	Strategy	Clinical trial #	References
Evusheld™	AstraZeneca	EUA	2x IgGs mixture	125 mg x two injections	IM	INJ	Px (long term)	NCT04625725 (ANR)	[497]
REGEN-COV™	Regeneron	EUA; Phase III	2x IgGs mixture	1200 mg^a	SC	INJ	Rx	NCT04452318 (C)	[498]
CT-P63 and CT-P59	Celltrion	Phase III	2x IgGs mixture	ND	INH	NEB	Rx	NCT05224856 (NYR)	[499]
Xevudy™ (UK); Sotrovimab (VIR-7831)	Vir	EUA; Phase II/III	IgG	250 mg^a, 500 mg^a	IM	INJ	Rx	NCT04913675 (ANR)	[209]
AZD7442	AstraZeneca	Phase III	2x IgGs mixture	300 mg ^a	IM	INJ	Rx	NCT04625972 (ANR)	[211]
MAD0004108	Toscana Life Sciences Sviluppo	Phase II/III	IgG	100 mg^a, 400 mg^a	IM	INJ	Rx	NCT04952805 (R)	[221]
ADG20	Adagio	Phase II/III	IgG	400 mg^a	IM	INJ	Px/Rx	NCT04859517 (R), NCT04805671 (R)	[219]
BI 767551 (DZIF-10c) ^c	Boehringer Ingelheim	Phase II/III	IgG	ND	INH	NEB	Rx	NCT04894474 (W)	[227]
STI-2099 (COVI-DROPS)	Sorrento	Phase II	IgG	10-40 mg^a	IN	Drops	Rx	NCT04906694 (NYR), NCT04900428 (R)	[226]
IGM-6268 (CoV-14)	IGM Biosciences	Phase I	IgM	7.5 mg dose/day ^a	IN	Drops	Px/Rx	NCT05160402 (R), NCT05184218 (R)	[245, 246, 410]
IgY-110	Stanford	Phase I	IgY	2-24 mg^a	IN	Drops	Rx	NCT04567810 (C)	[500]
EU126-M2	Eureka	PC	IgG	1.25–10 mg/kg^b	IN	Drops	Px	NA	[501, 502]
Nb15-NbH-Nb15	Abrev Biotech-nology Co., Ltd.	PC	Bispecific nanobody	10 mg/kg^b	IN	Drops	Px/Rx	NA	[503]
PiN21	University of Pittsburg	PC	Nanobody	0.2 mg/kg^b	IN	NEB	Px	NA	[253]
1212C2 ^d	Aridis	PC	IgG	0.6 mg/kg^b	INH	NEB	Px/Rx	NA	[251]
AUG-3387	TFF Pharma-ceuticals/Augmenta Bioworks	PC	IgG	0.3-1.0 mg/kg^b	INH	Dry powder	Px/Rx	NA	[504]
STI-9199 ^e (COVISHIELD™ IN)	Sorrento Therapeutics, Inc/Mount Sinai	PC	Human IgG1-LALA	0.5 mg/kg^b	IN	Drops	Rx	NA	[254]

ANR active not recruiting, C completed, EUA emergency use authorization granted, IM intramuscular, IN intranasal, INH inhalation, INJ injection, MOA mode of administration, NA not applicable, NCT National Clinical Trial (registry), ND not disclosed, NEB nebulizer, NYR not yet recruiting, PC preclinical, Px prophylaxis, R recruiting, ROA route of administration, Rx therapeutic treatment, SC subcutaneous, SOD stage of development, W withdrawn (from clinical development)

^aClinical dose in mg (total)

^bEfficacious preclinical dose in mg/kg

^cDiscontinued from development 7/26/21

^dPreclinical study was with antibody 1212C2, but plans are to move forward with AR-712, a cocktail consisting of two anti-SARS-CoV-2 IgGs [505]

^eSTI-9199 is IN formulation of STI-9167, which has been shown to have strong neutralization activity against Omicron